Intuniv nod brings Japan in tune with west on ADHD drug

4 April 2017

Ireland-headquartered Shire (LSE: SHP) has announced that its partner in Japan, Shionogi (TYO: 4507), has received the approval of the Japanese Ministry of Health, Labor and Welfare to manufacture and market Intuniv (guanfacine hydrochloride prolonged release).

Already approved in the USA, Canada and Europe, Intuniv is a once-daily non-stimulant indicated for attention deficit hyperactivity disorder (ADHD) in children and adolescents from six to 17 years old.

Non-stimulant medications such as Intuniv, a selective alpha-2A adrenergic receptor agonist, are an important alternative to stimulants for some ADHD patients. Phase III trials have shown that Intuniv provides significantly improved ADHD symptom control versus placebo and that it has a well-documented safety profile across the dose range.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK